v3.26.1
Warrants - Schedule of Key Inputs into Monte Carlo Simulation (Details)
Jun. 30, 2026
Dec. 31, 2025
Dec. 31, 2024
Class of Warrant or Right [Line Items]      
Warrants and rights outstanding, term (year) 3 months 21 days 9 months 21 days  
Measurement Input, Risk Free Interest Rate [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 0.041 0.0383  
Measurement Input, Option Volatility [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 2.762 2.004  
Measurement Input, Share Price [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 0.039 0.0374  
Preferred Tranche B Warrants [Member]      
Class of Warrant or Right [Line Items]      
Warrants and rights outstanding, term (year)     2 months 23 days
Preferred Tranche B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs     0.0393
Preferred Tranche B Warrants [Member] | Measurement Input, Option Volatility [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs     0.75
Preferred Tranche C Warrants [Member]      
Class of Warrant or Right [Line Items]      
Warrants and rights outstanding, term (year) [1] 2 years 4 months 28 days 2 years 10 months 28 days  
Preferred Tranche C Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs [1] 0.0414 0.0354  
Preferred Tranche C Warrants [Member] | Measurement Input, Option Volatility [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 1.055 1.05  
Preferred Tranche C Warrants [Member] | Preferred Series A [Member] | Measurement Input, Share Price [Member]      
Class of Warrant or Right [Line Items]      
Warrants, outstanding inputs 3.1799 3.0495  
[1] Reflects a probability-weighted input derived from multiple Black-Scholes calculations. These calculations incorporate the Company’s estimated probability of survival, assuming SABS’ intellectual property yields positive results in forthcoming clinical trials, allowing the Company to continue as a going concern rather than face dissolution before 2028. The probability of survival was 57.5% and 40.0% as of June 30, 2026 and December 31, 2025, respectively.